Pretomanid in drug-resistant tuberculosis: a profile of its use
online resourceposted on 2020-09-10, 07:52 authored by Matt Shirley
Compliance with ethical standards
Funding: The preparation of this review was not supported by any external funding.Conflict of interest: M. Shirley is an employee of Adis International Ltd./Springer Nature, is responsible for the article content and declares no conflicts of interest.
Additional information about this Adis Drug Review can be found here
Pretomanid, a nitroimidazoxazine antimycobacterial agent, presents a valuable option for the treatment of adults with pulmonary extensively drug-resistant (XDR) tuberculosis (TB) or treatment-intolerant or nonresponsive multidrug-resistant (MDR)-TB when used as part of an all-oral combination regimen with bedaquiline and linezolid. In the pivotal phase III Nix-TB trial, a combination regimen of pretomanid, bedaquiline, and linezolid for 6 months had a high treatment success rate. Besides the demonstrated effectiveness, the pretomanid, bedaquiline, and linezolid combination has other benefits, including the convenience of oral administration, a relatively short treatment duration, and a relatively low potential for drug-drug interactions.
© Springer Nature Switzerland AG 2020